Review article: Patient-level outcomes: The missing link

Nephrology

Volumn 14, Issue 4, 2009, Pages 443-451

  O'Shaughnessy, Denise V ^a,b   Elder, Grahame J ^c,d  

^a WESTMEAD HOSPITAL   (Australia)

^b Sydney Dialysis Centre   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Functional domains; Health related quality of life; Patient level outcomes; Testing instruments

Indexed keywords

CALCITRIOL; PARICALCITOL;

BONE DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CLINICAL RESEARCH; COMORBIDITY; DRUG EFFICACY; DYNAMOMETER; EXERCISE; GRIP STRENGTH; HEALTH SURVEY; HUMAN; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RENAL OSTEODYSTROPHY; REVIEW; TREATMENT OUTCOME;

COMORBIDITY; HEALTH STATUS INDICATORS; HUMANS; QUALITY OF LIFE; RENAL INSUFFICIENCY, CHRONIC; RENAL OSTEODYSTROPHY; RISK FACTORS;

EID: 67650739647     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2009.01136.x     Document Type: Review

References (48)

1. Block G, Danese M, Kim J, LaBrecque J, Klassen P. Elevated PTH and Ca x p levels are associated with increased hospitalization in hemodialysis patients. Am. J. Kidney Dis. 2003 41 : A15, 15 Abstract).
2. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. 2004 15 : 2208 18.
3. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J. Am. Soc. Nephrol. 2001 12 : 2131 8.
4. Marco MP, Craver L, Betriu A, Belart M, Fibla J, Fernandez E. Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population. Kidney Int. Suppl. 2003 85 : S111 14.
5. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006 70 : 771 80.
6. Young EW, Albert JM, Satayathum S et al. Predictors and consequences of altered mineral metabolism: The dialysis outcomes and practice patterns study. Kidney Int. 2005 67 : 1179 87.
7. Tentori F, Blayney MJ, Albert JM et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am. J. Kidney Dis. 2008 52 : 519 30.
8. Strippoli GF, Palmer S, Tong A, Elder G, Messa P, Craig JC. Meta-analysis of biochemical and patient-level effects of calcimimetic therapy. Am. J. Kidney Dis. 2006 47 : 715 26.
9. Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GF. Meta-analysis: Vitamin D compounds in chronic kidney disease. Ann. Intern. Med. 2007 147 : 840 53.
10. Seliger SL, Weiss NS, Gillen DL et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int. 2002 61 : 297 304. (Pubitemid 34075157)
11. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 2005 353 : 238 48.
12. Rakhit DJ, Marwick TH, Armstrong KA, Johnson DW, Leano R, Isbel NM. Effect of aggressive risk factor modification on cardiac events and myocardial ischaemia in patients with chronic kidney disease. Heart 2006 92 : 1402 8.
13. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 2006 355 : 2085 98.
14. Strippoli GF, Craig JC, Manno C, Schena FP. Hemoglobin targets for the anemia of chronic kidney disease: A meta-analysis of randomized, controlled trials. J. Am. Soc. Nephrol. 2004 15 : 3154 65.
15. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N. Engl. J. Med. 2006 355 : 2071 84.
16. Paniagua R, Amato D, Vonesh E et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J. Am. Soc. Nephrol. 2002 13 : 1307 20.
17. Eknoyan G, Beck GJ, Cheung AK et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N. Engl. J. Med. 2002 347 : 2010 19.
18. Teng M, Wolf M, Ofsthun MN et al. Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J. Am. Soc. Nephrol. 2005 16 : 1115 25.
19. Tentori F, Hunt WC, Stidley CA et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 2006 70 : 1858 65.
20. Wolf M, Shah A, Gutierrez O et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007 7 : 1004 13.
21. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N. Engl. J. Med. 2003 349 : 446 56.
22. Tentori F, Albert JM, Young EW et al. The survival advantage for haemodialysis patients taking vitamin D is questioned: Findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol. Dial. Transplant. 2009 24 : 963 72.
23. Suki WN, Zabaneh R, Cangiano JL et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007 72 : 1130 7.
24. St Peter WL, Liu J, Weinhandl E, Fan Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: A secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am. J. Kidney Dis. 2008 51 : 445 54.
25. Chassany O, Sagnier P, Marquis P, Fullerton S, Aaronson N. Patient-reported outcomes: The example of health-related quality of life: A European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Inf. J. 2002 36 : 209 38.
26. Mix TC, Brenner RM, Cooper ME et al. Rationale-Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease. Am. Heart J. 2005 149 : 408 13.
27. Ware JE Jr. Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care 1992 30 : 473 83.
28. Hays RD, Kallich JD, Mapes DL, Coons SJ, Carter WB. Development of the kidney disease quality of life (KDQOL) instrument. Qual. Life Res. 1994 3 : 329 38.
29. EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990 16 : 199 208.
30. DeOreo PB. Hemodialysis patient-assessed functional health status predicts continued survival, hospitalization, and dialysis-attendance compliance. Am. J. Kidney Dis. 1997 30 : 204 12.
31. Mapes DL, Lopes AA, Satayathum S et al. Health-related quality of life as a predictor of mortality and hospitalization: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int. 2003 64 : 339 49.
32. Australian Bureau of Statistics. National Health Survey: SF-36 population norms, Australia. Canberra: ABS, 1997.
33. Ware JE Jr. SF-36 health survey update. Spine 2000 25 : 3130 9.
34. Ware JEJ. The SF-36 Health Survey: An update. In : Maruish ME (ed.). The Use of Psychological Testing for Treatment and Planning Outcomes Assessment, 3rd edn. Manwah, NJ : Lawrence Erlbaum Associates, 2004 693 718.
35. Ware JE Jr., Kosinski M, Gandek B et al. The factor structure of the SF-36 Health Survey in 10 countries: Results from the IQOLA Project. International Quality of Life Assessment. J. Clin. Epidemiol. 1998 51 : 1159 65.
36. Rao S, Carter WB, Mapes DL et al. Development of subscales from the symptoms/problems and effects of kidney disease scales of the kidney disease quality of life instrument. Clin. Ther. 2000 22 : 1099 111.
37. Rettig RA, Sadler JH, Meyer KB et al. Assessing health and quality of life outcomes in dialysis: A report on an Institute of Medicine workshop. Am. J. Kidney Dis. 1997 30 : 140 55.
38. Cleemput I, Kesteloot K, Moons P et al. The construct and concurrent validity of the EQ-5D in a renal transplant population. Value Health 2004 7 : 499 509. (Pubitemid 39038459)
39. Schmidt RT, Toews JV. Grip strength as measured by the Jamar dynamometer. Arch. Phys. Med. Rehabil. 1970 51 : 321 7.
40. Robertson LD, Mullinax CM, Brodowicz GR, Miller RA, Swafford AR. The relationship between two power-grip testing devices and their utility in physical capacity evaluations. J. Hand Ther. 1993 6 : 194 201.
41. Hanten WP, Chen WY, Austin AA et al. Maximum grip strength in normal subjects from 20 to 64 years of age. J. Hand Ther. 1999 12 : 193 200. (Pubitemid 29385997)
42. Richards LG, Olson B, Palmiter-Thomas P. How forearm position affects grip strength. Am. J. Occup. Ther. 1996 50 : 133 8
43. Guralnik JM, Simonsick EM, Ferrucci L et al. A short physical performance battery assessing lower extremity function: Association with self-reported disability and prediction of mortality and nursing home admission. J. Gerontol. 1994 49 : M85 94.
44. Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N. Engl. J. Med. 1995 332 : 556 61.
45. Maki BE, Holliday PJ, Topper AK. Fear of falling and postural performance in the elderly. J. Gerontol. 1991 46 : M123 31.
46. Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW, Berman LB. The 6-minute walk: A new measure of exercise capacity in patients with chronic heart failure. Can. Med. Assoc. J. 1985 132 : 919 23.
47. Lord SR, Menz HB. Physiologic, psychologic, and health predictors of 6-minute walk performance in older people. Arch. Phys. Med. Rehabil. 2002 83 : 907 11.
48. Lord SR, Murray SM, Chapman K, Munro B, Tiedemann A. Sit-to-stand performance depends on sensation, speed, balance, and psychological status in addition to strength in older people. J. Gerontol. A Biol. Sci. Med. Sci. 2002 57 : M539 43.